BC Week In Review | May 26, 2017
Clinical News

AbbVie starts Phase I for TRAIL-receptor agonist in cancer

Apogenix AG (Heidelberg, Germany) said partner AbbVie Inc. (NYSE:ABBV) began a Phase I trial to evaluate ABBV-621 (APG880) in 92 patients with relapsed or refractory solid tumors, non-Hodgkin’s lymphoma (NHL) or acute myelogenous leukemia (AML)....
Items per page:
1 - 1 of 1